Assessing Essentiality Leishmania donovani Nitroreductase Role Nitro Drug Activation
Susan Wyllie, Stephen Patterson, Alan H. Fairlamb
Division Biological Chemistry Drug Discovery, Wellcome Trust Biocentre, College Life Sciences, University Dundee, Dundee, Scotland, United Kingdom
 nitroimidazole fexinidazole potential safe effective oral drug therapy treatment visceral leishmaniasis. date, nitroheterocyclics used treatment leishmaniasis, relatively little known mecha-
nism action. African trypanosomes, nitro drugs reductively activated type nitroreductase (NTR), absent mam-
malian cells. Modulation nitroreductase levels Trypanosoma brucei directly affected sensitivity nitro compounds, reduced concentrations enzyme leading moderate nitro drug resistance. view progression fexinidazole clinical development visceral leishmaniasis, assess essentiality nitroreductase Leishmania donovani effect modulating nitroreductase levels susceptibility fexinidazole. failure directly replace endogenous
copies NTR gene, presence ectopic copy gene, suggests NTR gene essential growth survival L. donovani promastigotes. Loss single chromosomal copy L. donovani NTR gene resulted parasites mildly resistant (<2-fold) predominant vivo metabolite fexinidazole, parasites overexpress-
ing NTR 18-fold susceptible. data confirm Leishmania NTR plays pivotal role fexinidazole activation.
Reliance single enzyme prodrug activation leave fexinidazole vulnerable emergence drug resistance.   essentiality NTR L. donovani promastigotes, combined limited resistance shown NTR single
knockout cells, suggests potential spread NTR-based resistance fexinidazole limited.



V    isceral leishmaniasis (VL), caused protozoan parasite
     Leishmania donovani, second largest parasitic killer malaria, 200 million people currently risk                                                                                      zole successfully completed, phase II/III trials                                                                                      scheduled later year (7). Fexinidazole potential                                                                                      safe effective oral drug therapy treatment visceral
infection. 95  cases, death prevented timely                     leishmaniasis (8). Administration daily oral regimen appropriate drug therapy (1);  current treatment options                     200 mg fexinidazole kg body weightâ«º1 5 days far ideal. India, Bangladesh, Nepal, epicenter                   suppress infection mouse model visceral leishmaniasis VL infection, 60  worldâ€™s reported cases (2),                     98.4 , potency comparable seen current 
certed efforts eradicate disease 2015.                   line antileishmanial miltefosine. light findings, fexini-
present, best available treatments anthroponotic VL                      dazole scheduled enter phase II clinical trials miltefosine liposomal amphotericin B. Undoubtedly,                          treatment visceral leishmaniasis Sudan (Bernard PÃ©coul,
drugs vastly superior previous therapies,                  DNDi, personal communication).
limitations. principal drawbacks miltefosine terato-                      Nitroheterocyclics used treatment genicity, prolonged treatment regimen, high resistance po-                       leishmaniasis, result, relatively little known tential (3). Problems associated amphotericin B include high                    mechanism action leishmania parasites. African try-
treatment costs, intravenous route administration,                      panosomes, mode action nifurtimox involves reductive
responsiveness Sudanese VL patients (4).                       activation type NADH-dependent nitroreductase (NTR),
mains definite urgent need strengthen range treat-                   resulting generation cytotoxic, unsaturated open-chain
ment options VL.                                                                 nitrile derivative (9). Overexpression leishmanial homolog
    search effective treatments neglected dis-                   nitroreductase L. donovani increase sensi-
eases, renewed chemotherapeutic                       tivity fexinidazole 15-fold sensitivity nifurtimox 19-fold
potential nitroheterocyclic compounds. stems                        (8), indicating similar mechanisms involved L.
largely success nifurtimox-eflornithine combination                      donovani African trypanosome, Trypanosoma brucei. Ge-
therapy (NECT) treatment Gambian form human                        netic studies indicate nitroreductase essential sur-
African trypanosomiasis (HAT) (5). Treatment NECT,                          vival African trypanosome vitro (10).  modula-
sisting oral nifurtimox 10 days eflornithine infusions 7 days, resulted cure rates ca. 97 , leading inclusion Essential Medicines List (5).                           Received 29 August 2012 Returned modification 11 October 2012
success nifurtimox NECT prompted Drugs                            Accepted 26 November 2012
Neglected Diseases Initiative (DNDi) undertake comprehen-                          Published ahead print 3 December 2012
sive screen 700 nitroheterocyclic compounds antiparasitic                        Address correspondence Susan Wyllie, s.wyllie@dundee.ac.uk.
activity. result, 2-substituted 5-nitroimidazole fexinida-                     Copyright Â© 2013, American Society Microbiology. Rights Reserved.
zole (Hoe 239), shown antitrypanosomal activity al-                       doi:10.1128/AAC.01788-12 30 years ago (6), rediscovered. Subsequently, phase                          authors paid fee allow immediate free access article.
clinical trials treating African sleeping sickness fexinida-


February 2013 Volume 57 Number 2                                  Antimicrobial Agents Chemotherapy         p. 901â€“906                                 aac.asm.org   901
 Wyllie et al.



tion nitroreductase levels trypanosomatids             TABLE 1 Cloning primers
shown directly affect sensitivity nitro compounds vitro,             Primer                    Primer sequencea reduced enzyme activity leading moderate nitro drug                5=UTR-NotI_s          5=-ataagaatgcggccgcAGTCATGTGATGGTG
sistance (10). view progression fexinidazole clin-                                   GTTTACGGCA-3=
ical development visceral leishmaniasis, clear po-         5=UTR-HindIII/PmeI_as 5=-gtttaaacttacggaccgtcaagcttTGTAGTTTCT
tential nitroreductase-mediated drug resistance                                     CTTGCTGCTTTCC-3=
addressed Leishmania spp. mind, assess               3=UTR-PmeI/BamHI_s 5=-gacggtccgtaagtttaaacggatccTTTAGACTCG essentiality nitroreductase Leishmania donovani                                      GCACCAGAGATGAGA-3= effect modulation nitroreductase levels suscepti-            3=UTR-NotI_as         5=-ataagtaagcggccgcCCAAGACAGCAGCA
bility nitro drugs.                                                                                 GCCGGTCGTGA-3=
                                                                              LdNTR-BamHI_s         5=-ggatccATGCTTCGCCGCAGTCGCCGCTT-3=
                                                                              LdNTR-BamHI_as        5=-ggatccTAGAACTTGTTCCACCGCACGGT-3=
MATERIALS METHODS                                                                                                                                         Capital letters represent nucleotides corresponding gene sequences L. infantum;
Ethics statement. animal experiments approved Ethical         lowercase letters represent additional sequences used generating constructs.
Review Committee University Dundee performed            Restriction endonuclease sites underlined.
der Animals (Scientific Procedures) Act 1986 (United Kingdom Home
Office Project License PPL 60/4039) accordance European
Communities Council Directive (86/609/EEC).
    Cell lines culture conditions. clonal Leishmania donovani              recovery vector generated amplifying LdBOB nitrore-
cell line LdBOB (derived MHOM/SD/62/1S-CL2D) grown                ductase gene genomic DNA using LdNTR-BamHI sense promastigotes 26Â°C modified M199 medium, described previously        antisense primers. PCR product cloned pCR-Blunt
(11).                                                                         II-TOPO vector (Invitrogen) sequenced. pCR-Blunt II-
    Test compounds. Fexinidazole sulfone synthesized described         TOPO-LdNTR construct digested BamHI, frag-
previously (8). Compound purity determined liquid chromatog-           ment cloned pIR1SAT expression vector (14), resulting raphyâ€“mass spectrometry (LC-MS) â±–95 .                 pIR1SAT-LdNTR construct.
stocks nifurtimox used study provided Bayer, Argentina,         Generation LdBOB transgenic cell lines. Mid-log-phase L. don- kind gift. Nitrofurazone miltefosine purchased Sigma-      ovani promastigotes (LdBOB) transfected knockout Aldrich                                                                   recovery constructs using Human T-Cell Nucleofector kit     vitro drug sensitivity assays. examine effects test com-     Amaxa Nucleofector electroporator (program V-033). Following trans-
pounds growth, triplicate promastigote cultures seeded 1 â«»       fection, cells allowed grow 16 24 h modified M199 
105 parasites mlâ«º1. Parasites grown 5-ml cultures presence     dium (11) 10  fetal calf serum prior appropriate drug selection drug 72 h, 200-â?®l aliquots culture added    (100 â?®g nourseothricin mlâ«º1, 50 â?®g hygromycin mlâ«º1, 20 â?®g puro- 96 plates; 50 â?®M resazurin added  fluores-       mycin mlâ«º1). Cloned cell lines generated limiting dilution, main-
cence (excitation wavelength, 528 nm; emission wavelength, 590 nm)        tained selective medium, removed drug selection measured 4 h incubation (12). Data processed using    passage prior experiments.
GRAFIT (version 5.0.4; Erithacus Software) fitted 2-param-           Southern blot analyses transgenic L. donovani cell lines. ORF
eter equation, data corrected background fluorescence,      5= UTR LdBOB NTR amplified PCR (using primers obtain effective concentration inhibiting growth 50  (EC50):        listed Table 1 cloning L. donovani NTR [LdNTR] knock-
                                    100                                       constructs) PCR DIG Probe Synthesis kit (Roche). 

                                      å†‰ å†Š
                          y â«½                                                 sulting digoxigenin (DIG)-labeled products used probes. Samples
                                      å…³Iå…´     m
                                                                              genomic DNA (5 â?®g) wild-type (WT) transgenic cell lines
                                1 â«¹
                                     EC50                                     digested appropriate restriction endonucleases, diges- equation,   represents inhibitor concentration m     tion products separated 0.8  agarose gel trans-
slope factor. experiments repeated times,     ferred positively charged nylon membrane (Roche). membrane
data presented weighted means plus weighted standard devia-        hybridized overnight DIG Easy Hyb solution (Roche) 42Â°C tions (12).                                                                   DIG-labeled TRYS ORF 5= UTR probes (2 â?®l PCR product).
    Amastigote drug sensitivity assays. macrophage drug sensitivity        Following hybridization, membranes washed twice low-strin-
assays carried described previously (8), using starch-elicited    gency conditions (25Â°C, 5 min, SSC 0.1  sodium dodecyl sulfate
peritoneal macrophages harvested BALB/c mice. Macrophages           [SDS]) twice high-stringency conditions (68Â°C, 15 min, 0.5â«»
infected metacyclic promastigotes ratio 10 promastigotes 1    SSC 0.1  SDS), 1â«» SSC comprises 150 mM sodium chloride
macrophage.                                                                   50 mM sodium citrate (pH 7.0). Bound probe detected using
    Generation knockout, overexpression, recovery constructs.          DIG immunological detection kit (Roche) according manufac- primers used generate constructs genetic manipulation         turerâ€™s instructions.
designed using Leishmania infantum nitroreductase (NTR) sequence               Northern blot analyses transgenic L. donovani cell lines. Total GeneDB (LinJ.05.0660) template (Table 1). accuracy         RNA isolated mid-log-phase L. donovani (LdBOB) promasti-
constructs assembled verified sequencing. NTR gene replacement         gotes (1 â«»108) using RNeasy Plus kit (Qiagen). Northern blot
cassettes generated amplifying region DNA encompassing       analysis RNA samples carried separating RNA (10 â?®g) 5= untranslated region (5= UTR), open reading frame (ORF), 3= UTR         1  (wt/vol) agarose-formaldehyde gel transferring RNA LdBOB NTR genomic DNA primers 5=UTR-NotI_s                   positively charged nylon membrane (Roche). membrane hybrid-
3=UTR-NotI_as, using Pfu polymerase. sequence used         ized overnight DIG Easy Hyb solution (Roche) 68Â°C DIG-
template amplification individual regions used assem-   labeled NTR RNA probe, generated NTR ORF using DIG
bly replacement cassettes containing selectable drug resistance        Northern starter kit (Roche). Following hybridization, membranes genes encoding puromycin N-acetyltransferase (PAC) hygromycin             washed, bound probe detected manner identical phosphotransferase (HYG), constructed exactly described previously         described Southern blots. Levels NTR transcripts cell
(13).                                                                         line directly compared densitometry using ImageJ program.


902 aac.asm.org                                                                                                           Antimicrobial Agents Chemotherapy
                                                                                                                Essentiality Leishmania donovani Nitroreductase




                                                                                  FIG 2 Analysis NTR transcript levels Northern blotting.   RNA sam-
                                                                                  ples (10 â?®g) prepared WT (lane 1), SKO (lane 2), OE (lane 3)
                                                                                  promastigotes analyzed Northern blotting. Blots hybridized
                                                                                  RNA probe generated LdBOB NTR gene. (B) Ethidium bro-
                                                                                  mide staining RNA samples loaded agarose-formaldehyde gel prior                                                                                   transfer.




                                                                                  replacing second copy PAC. ectopic copy NTR
                                                                                  inserted ribosomal DNA (rDNA) locus SKO
                                                                                  cell line using pIR1SAT vector, encodes FIG 1 Genotypic analysis WT, SKO, rDKO cell lines.   Southern blot       nourseothricin resistance gene (SAT), resulting constitutive
analysis SalI-digested genomic DNA (â¬ƒ5 â?®g) wild-type L. donovani          expression NTR. clones rDKO promastigotes 
(LdBOB) cells (lane 1), NTR single knockout (HYG) cells (lane 2), NTR single      firmed Southern blotting lost copies 
knockout (HYG) cells constitutively expressing NTR (lane 3), NTR double           dogenous NTR genes (Fig. 1A). failure directly replace knockout (PAC HYG) cells constitutively expressing NTR (lane 4),                                                                                   endogenous copies NTR, presence ecto-
â€œfalseâ€? NTR double knockout (PAC HYG) cells (lanes 5 7). NTR
ORF probe shows allelic LdNTR 6.5 kb, ectopic copy LdNTR â¬ƒ9 kb,      pic copy gene, strongly suggests NTR gene essen- chromosomally rearranged copy NTR 5.5 kb (*). (B) Southern blot       tial successful growth survival L. donovani promas-
analysis NotI-digested genomic DNA (â¬ƒ5 â?®g) wild-type L. donovani          tigotes culture.
(LdBOB) cells (lane 1) NTR single knockout (HYG) cells (lane 2) probed            Modulation NTR levels L. donovani alters sensitivity 5= UTR NTR. (C) Structure NTR locus NTR single knock- (HYG) cells. Black bars represent 5= UTR region upstream open      nitro drugs. Modulation nitroreductase levels Trypano-
reading frame NTR, used probe Southern blot analysis.        soma brucei Trypanosoma cruzi shown directly
NotI sites expected fragment sizes shown. endogenous NTR gene        affect sensitivity nitro compounds vitro, reduced 
contains NotI site results 2-kb band. Successful replacement   centrations enzyme leading nitro drug resistance (10). allelic copy endogenous gene HYG, does contain NotI
site, results 9-kb fragment.
                                                                                  determine case L. donovani, sensi-
                                                                                  tivities WT, SKO, NTR-overexpressing (OE) promasti-
                                                                                  gotes number nitroheterocyclic compounds assessed.
                                                                                   modulation NTR transgenic cell lines 
RESULTS                                                                           firmed comparing NTR transcript levels Northern blotting
Generation NTR-complemented null mutants. essential-                       (Fig. 2). NTR transcript levels 1.7-fold lower SKO parasites
ity L. donovani nitroreductase assessed classical gene                  4.2-fold higher OE parasites WT parasites, 
replacement, NTR sequentially replaced drug resis-                  termined densitometry. expected, changes level tance genes. copy NTR gene replaced                 NTR cells correlated directly relative sensitivi-
hygromycin resistance gene (HYG, encoding hygromycin phos-                        ties nifurtimox nitrofurazone, nitrofuran compounds
photransferase) homologous recombination subsequent                        known undergo NTR-catalyzed 2-electron reduction try-
selection hygromycin resistance, generating single knockout                 panosomes (Table 2). Promastigotes overexpressing NTR (SKO) cell line (Fig. 1A B). SKO promastigotes grew                    16- 4-fold sensitive WT cells nifur- rate culture homozygotes, cell density.                timox nitrofurazone, respectively. Conversely, SKO parasites
Attempts create null mutant directly                    sensitive compounds, EC50s 7.2 2.5
placing second allelic copy puromycin N-acetyltrans-                 â?®M nifurtimox nitrofurazone, respectively, compared ferase gene (PAC). separate occasions, promastigotes                   values 5.0 1.4 â?®M WT cells. Similar NTR level-depen-
sistant hygromycin puromycin recovered                      dent shifts sensitivity observed cells treated fexini-
transfections.  Southern blot analysis genomic DNA                     dazole sulfone, predominant active metabolite nitroim- multiple clones putative double knockout (DKO)                      idazole fexinidazole vivo (8, 15). parasites overexpressing
cells revealed retained endogenous copy                  NTR 18-fold susceptible fexinidazole sulfone NTR generated additional gene copy, presumably                    WT parasites, SKO promastigotes marginally sensitive chromosomal rearrangement (Fig. 1A). Consequently, res-                      (â¬?2-fold [Table 2]). contrast, concomitant shift cued double knockout (rDKO) cell line generated intro-                     sensitivity promastigotes alkyl phospholipid milte-
ducing ectopic copy NTR SKO promastigotes prior                     fosine.  NTR plays crucial role activation fexini-


February 2013 Volume 57 Number 2                                                                                                               aac.asm.org 903
 Wyllie et al.



TABLE 2 Sensitivities WT, SKO, OE promastigotes standard drugs experimental nitro compounds
                                                                                        EC50a (Hill slope) L. donovani
Compound                                Structure                                       WT                                OE                              SKO


Fexinidazole sulfone                                                                    7.2 â«¾ 0.2 (5.4)                   0.4 â«¾ 0.01b (2.3)               12.6 â«¾ 0.1b (2.3)



Nifurtimox                                                                              5.0 â«¾ 0.05 (4.7)                  0.32 â«¾ 0.01b (2.8)              7.23 â«¾ 0.08b (2.5)



Nitrofurazone                                                                           1.43 â«¾ 0.02 (5.5)                 0.35 â«¾ 0.01b (2.4)              2.5 â«¾ 0.02b (2.5)


Miltefosine                                                                             7.7 â«¾ 0.1 (3.5)                   8.16 â«¾ 0.05 (3.8)               7.9 â«¾ 0.2 (3.3)
     Expressed micromolar concentrations. Results weighted means standard errors independent experiments.
b
    P, â¬?0.0001 comparison WT Studentâ€™s t test.



dazole metabolites L. donovani, NTR depletion cells lead minor levels resistance promastigotes.
    NTR modulation intracellular amastigotes. manner
identical seen insect-stage promastigotes, potency fexinidazole sulfone intracellular mammalian-stage amasti-
gotes materially altered changes cellular NTR levels.
Metacyclic promastigotes (WT, SKO, OE) used infect
starch-elicited mouse peritoneal macrophages, EC50s determined cell line following 72-h incubation vary-
ing concentrations drug (Fig. 3A). Intracellular amastigotes
overexpressing NTR approximately 9-fold sensitive fexinidazole sulfone (EC50, 0.7 â?®M) WT parasites (EC50, 6.4
â?®M), SKO parasites showed â¬?2-fold decrease sensitiv-
ity drug (EC50, 8.8 â?®M). finding loss single
copy NTR gene leads fexinidazole resistance L. dono-
vani keeping resistance mechanisms iden-
tified laboratory-generated fexinidazole-resistant T. brucei cell
lines (15).  noted EC99 fexinida-
zole sulfone intracellular SKO amastigotes (78.5 â?®M), cal-
culated using Hill slopes, markedly different cal-
culated WT amastigotes (69.6 â?®M).
    Loss allelic copy NTR did diminish infectivity SKO metacyclic promastigotes: mean number amasti-
gotes infected macrophage overall percentage 
fected macrophages untreated controls comparable seen WT-infected macrophage cultures (Fig. 3B C).  parasites overexpressing NTR did appear lose
â€œfitness.â€? number OE amastigotes infected mac-
rophage percentage macrophages infected OE                              FIG 3 Effects NTR modulation susceptibility fexinidazole sulfone.
                                                                                            susceptibilities amastigotes cultured starch-elicited mouse peritoneal
cell line significantly lower WT (P, 0.04                           macrophages determined.   EC50s fexinidazole sulfone 0.03, respectively).                                                                    WT (open circles), SKO (HYG) (filled circles), OE (open squares) para-
                                                                                            sites determined. EC50s 6.4 â«¾ 0.9, 8.8 â«¾ 0.7, 0.7 â«¾ 0.06 â?®M DISCUSSION                                                                                  fexinidazole sulfone WT, SKO, OE cell lines, respec-
                                                                                            tively. (B) mean number WT, SKO, OE amastigotes infecting mouse inability knock allelic copies NTR,                        peritoneal macrophages untreated control cultures determined. Differ-
presence ectopic copy gene, provides strong evidence                           ences number WT versus OE amastigotes infecting macrophages endogenous function NTR essential viability                          confirmed statistically significant (P â«½ 0.04) using unpaired Student t L. donovani promastigotes. true African                             test (*). (C) percentage macrophages infected WT, SKO, OE
                                                                                            amastigotes untreated control cultures determined. Differences trypanosome: NTR deleted bloodstream-form                                 percentage macrophages infected WT versus OE amastigotes T. brucei parasites (10). case South American try-                            confirmed statistically significant (P â«½ 0.03) using unpaired Student t
panosome T. cruzi, NTR-null mutants epimastigote (insect                             test (*). data means triplicate measurements.



904      aac.asm.org                                                                                                                   Antimicrobial Agents Chemotherapy
                                                                                                        Essentiality Leishmania donovani Nitroreductase



stage) unable differentiate infectious metacyclic trypo-     tion, rationale likelihood developing resis-
mastigotes infect mammalian cells (10).  NTR             tance single agent relatively high, likelihood activity appears absolute requirement virulence      developing resistance compounds significantly lower
trypanosomatids mammalian hosts. biological func-           (19). use drug combinations circumvent resistance
tions trypanosomal NTRs remain determined.              successful antimalarials (19), approach evidence enzymes play role             seriously considered treatment visceral
ubiquinone metabolism. Trypanosomal NTRs share fea-              leishmaniasis.  recent trial directly compared effi-
tures mitochondrial NADH dehydrogenases (10), enzymes               cacies potential short-course combination treatments
known catalyze transfer electrons NADH ubiqui-         standard monotherapy India (20).   leading generation ubiquinol (16). addition,        sults study confirm combination treatments
recent genomewide RNA interference (RNAi) target-sequencing              visceral leishmaniasis efficacious safe screen T. brucei demonstrated link nitro drug action,       reduce emergence drug-resistant parasites. pro-
ubiquinone biosynthesis, nitroreductases (17).         gression fexinidazole clinical development use
studies required order pinpoint precise essential      visceral leishmaniasis, work identify appropriate
biological function trypanosomal NTRs, clear     partner drug nitroimidazole way.
enzymes play crucial role activation nitro drugs. essentiality enzymes â€œTritrypâ€? parasites       ACKNOWLEDGMENTS makes attractive targets development novel          work supported grants (079838, 077705, 083481) chemotherapeutic agents undergo reductive activa-            H.F. Wellcome Trust (http://www.wellcome.ac.uk).
tion.
    Loss single chromosomal copy L. donovani NTR             REFERENCES
gene resulted parasites mildly resistant ni-      1. Ritmeijer K, Davidson RN. 2003. Medecins Sans FrontiÃ¨res interventions
troheterocyclic compounds, including predominant vivo                 kala-azar Sudan, 1989 â€“2003. Trans. R. Soc. Trop. Med. Hyg.
metabolite antileishmanial drug candidate fexinidazole.               97:609 â€“ 613. data, combined pronounced hypersensitivity dem-            2. Regional Technical Advisory Group Kala-azar Elimination. 2005.
                                                                             Report meeting, Manesar, Haryana, 20 â€“23 December 2004.
onstrated promastigotes overexpressing NTR, confirm                                                                              project IND CDR 714. SEA-VBC-88. World Health Organization
Leishmania NTR plays pivotal role activation nitro               Regional Office South-East Asia, New Delhi, India. http://www.searo
drugs general, mechanism action fexinidazole           int/LinkFiles/Kala_azar_VBC-88.pdf.
particular. Recent studies shown trypanosomal nitrore-          3. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. 2009.
ductases catalyze sequential 2-electron reduction nifurti-            Developments treatment visceral leishmaniasis. Expert Opin.
                                                                             Emerg. Drugs 14:395â€“ 410.
mox, resulting generation cytotoxic, unsaturated open-        4. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR,
chain nitrile derivative (9). remains seen                  Davidson R. 2007. Unresponsiveness AmBisome Sudanese
fexinidazole metabolites undergo similar 2-electron             patients kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101:19 â€“24.
duction catalyzed Leishmania nitroreductase. Importantly,          5. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S,
                                                                             Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, findings illustrate mechanism clinical resis-
                                                                             Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande
tance fexinidazole emerge. Reliance single enzyme              V. 2009. Nifurtimox-eflornithine combination therapy second-stage prodrug activation leave drugs fexinidazole vul-             African Trypanosoma brucei gambiense trypanosomiasis: multicentre,
nerable emergence drug resistance.  failure            randomised, phase III, non-inferiority trial. Lancet 374:56 â€“ 64. generate NTR-null promastigotes clearly suggests         6. Jennings FW, Urquhart GM. 1983. use 2 substituted 5-nitro-
                                                                             imidazole, Fexinidazole (Hoe 239) treatment chronic T. brucei
selective pressure Leishmania parasites retain NTR               infections mice.  Parasitenkd. 69:577â€“581.
activity. pressure added advantage limiting          7. Torreele E, Trunz BB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, maximum levels fexinidazole resistance achievable,               Pecoul B. 2010. Fexinidazole new oral nitroimidazole drug candidate
SKO promastigotes 2-fold resistant drug.            entering clinical development treatment sleeping sickness. PLoS
                                                                             Negl. Trop. Dis. 4:e923. doi:10.1371/journal.pntd.0000923.
recent studies T. cruzi, laboratory-generated benznidazole-
                                                                          8. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R,
resistant parasites lost single copy NTR         Read KD, Fairlamb AH. 2012. anti-trypanosome drug fexinidazole
gene, mutations arising remaining copy gene                shows potential treating visceral leishmaniasis. Sci. Transl. Med.
abolished enzyme activity (18).  â€œfunctional nullâ€?             4:119re1. doi:10.1126/scitranslmed.3003326.
parasites demonstrated reduced levels virulence          9. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation trypano-
                                                                             somal type nitroreductases generates cytotoxic nitrile metabolites. J.
capacity highly drug resistant T. cruzi parasites spread         Biol. Chem. 286:13088 â€“13095. population severely compromised.          